血管内皮生长因子及骨桥蛋白联合检测在非小细胞肺癌中的临床研究(1)
【摘要】目的：观察血清血管内皮生长因子(VEGF)及骨桥蛋白(OPN)联合检测在非小细胞肺癌临床中的应用价值。方法：采用酶联免疫吸附法(ELISA)对80例各期非小细胞肺癌患者行血清VEGF，OPN检测，同时对其中43例治疗有效的患者行治疗前后(放化疗或手术前后)的该两种肿瘤标志物血清水平比较。结果：VEGF在Ⅱ~Ⅲ期患者中平均值为(295.47±186.23)pg/ml，在Ⅳ期患者中则可达(398.64±205.67)pg/ml，差异有显著性(P0.05)。43例治疗有效者VEGF及OPN下降明显，分别由治疗前的(316.26±147.32)pg/ml和(61.27±18.38)ng/ml降至治疗后的(205.77±98.52)pg/ml和(32.06±11.53)ng/ml，差异有显著性(P0.05)，对于判断临床分期无明显作用。经治疗缓解的非小细胞肺癌患者血清中VEGF及OPN水平下降明显(P0.05)，it did not correlate with clinical TNM.The serum concentration of the two tumor markers decreased significantly in 43 patients who were effective after treatment，which was from (316.26±14.32)pg/ml and (61.27±18.38)ng/ml before treatment to (205.77±98.52)pg/ml and (32.06±11.53)ng/ml after treatment respectively(P, 百拇医药(胡春霞)